A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)

BRAF+MEK inhibitors extend life expectancy of patients with BRAF V600 mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this limitation. INTERIM was a phase 2 trial evaluating an intermittent dosing regimen.

Source: European Journal of Cancer - November 23, 2023 Category: Cancer & Oncology Authors: Alimu Dayimu, Avinash Gupta, Rubeta N Matin, Jenny Nobes, Ruth Board, Miranda Payne, Ankit Rao, Alberto Fusi, Sarah Danson, Bryony Eccles, Judith Carser, Ciara O ’Hanlon Brown, Neil Steven, Madhumita Bhattacharyya, Ewan Brown, Michael Gonzalez, Martin H Tags: Original Research Source Type: research